Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-05-21

Clinical Trial Update: A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107) [Phase 3]

View source ↗

Summary

Phase 3, two-part, 12-week trial of etoricoxib for rheumatoid arthritis has completed and results were posted on 2015-05-21.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Etoricoxib (etoricoxib)

Snippet

Sponsor: Organon and Co | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2015-05-21